Latest news with #JustinSmith
Sky News AU
a day ago
- Entertainment
- Sky News AU
‘Hell of a stretch': American Eagle ad sparks turmoil as Sydney Sweeney cops backlash
Columnist Justin Smith has commented on a new ad campaign for American Eagle which features actress Sydney Sweeney and has caused outrage on social media. 'I don't get it – I mean it's a pretty lame ad to be frank,' he told Sky News host Chris Kenny. 'I really don't see what the problem is with it – it's a hell of a stretch.'
Business Insider
4 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Oneview Healthcare Chess Depository Interests repr 1 (ONVVF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer (PFE) In a report released yesterday, Justin Smith from Bernstein maintained a Hold rating on Pfizer, with a price target of $30.00. The company's shares closed last Friday at $24.79, close to its 52-week low of $24.48. According to Smith is ranked #3539 out of 9922 analysts. Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, which is a 13.7% upside from current levels. In a report issued on July 22, TR | OpenAI – 4o also downgraded the stock to Hold with a $26.00 price target. In a report released yesterday, Martyn Jacobs from Bell Potter maintained a Buy rating on Oneview Healthcare Chess Depository Interests repr 1, with a price target of A$0.34. The company's shares closed last Friday at $0.16, equals to its 52-week high of $0.16. According to Jacobs is ranked #9692 out of 9922 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oneview Healthcare Chess Depository Interests repr 1 with a $0.23 average price target.
Globe and Mail
10-07-2025
- Business
- Globe and Mail
Bernstein Sticks to Its Hold Rating for Pfizer (PFE)
Bernstein analyst Justin Smith maintained a Hold rating on Pfizer yesterday and set a price target of $30.00. The company's shares closed yesterday at $25.62. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Smith covers the Healthcare sector, focusing on stocks such as Pfizer, AstraZeneca, and arGEN X. According to TipRanks, Smith has an average return of 3.4% and a 50.00% success rate on recommended stocks. Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $28.38, which is a 10.77% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target. Based on Pfizer's latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $13.72 billion and a net profit of $2.97 billion. In comparison, last year the company earned a revenue of $14.88 billion and had a net profit of $3.12 billion
Business Insider
09-07-2025
- Business
- Business Insider
Bernstein Sticks to Its Hold Rating for Pfizer (PFE)
Bernstein analyst Justin Smith maintained a Hold rating on Pfizer yesterday and set a price target of $30.00. The company's shares closed yesterday at $25.62. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Smith covers the Healthcare sector, focusing on stocks such as Pfizer, AstraZeneca, and arGEN X. According to TipRanks, Smith has an average return of 3.4% and a 50.00% success rate on recommended stocks. Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $28.38, which is a 10.77% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target. Based on Pfizer's latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $13.72 billion and a net profit of $2.97 billion. In comparison, last year the company earned a revenue of $14.88 billion and had a net profit of $3.12 billion
Sky News AU
03-07-2025
- Entertainment
- Sky News AU
‘I love the circus': Elon Musk – Donald Trump feud turns ugly
Columnist Justin Smith has commented on the feud between Elon Musk and US President Donald Trump which has been reignited and escalated due to the President's 'Big Beautiful Bill'. 'Thank God this grudge is back on; I was sad there for a while because it looked like that it was just going to fizzle out and go away, but thank goodness something reunited again,' Mr Smith told Sky News host Danica De Giorgio. 'I love it; I love the circus; I can't get enough.'
